Menu
Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 6
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]
Authors Kesayan T, Shaw J, Jones T, Staffetti J, Zesiewicz T
Received 10 August 2015
Accepted for publication 10 August 2015
Published 3 February 2016 Volume 2016:6 Pages 13—15
Kesayan T, Shaw JD, Jones TM, Staffetti JS, Zesiewicz TA. Degenerative Neurological and Neuromuscular Disease 2015;5:63–72.
The authors would like to correct the following errors: on page 64; paragraph 1, “RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 6 mg/24 hours, with recommended titration of 2 mg/24 hours weekly.5 For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours.7” should be “RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 8 mg/24 hours (2–6 mg/24 hours in the US), with recommended titration of 2 mg/24 hours weekly.5 For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recommended dose of 16 mg/24 hours (4–8 mg/24 hours in the US).5”
View original article by Kesayan et al
© 2016 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.